Does the media refer more to RAPP or UPB?

In the previous week, Rapport Therapeutics had 1 more articles in the media than Upstream Bio. MarketBeat recorded 4 mentions for Rapport Therapeutics and 3 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 1.23 beat Rapport Therapeutics' score of 0.58 indicating that Upstream Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapport Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Upstream Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to UPB or OCUL?

In the previous week, Ocular Therapeutix had 5 more articles in the media than Upstream Bio. MarketBeat recorded 8 mentions for Ocular Therapeutix and 3 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 1.23 beat Ocular Therapeutix's score of -0.17 indicating that Upstream Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Upstream Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ocular Therapeutix 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer SRPT or UPB?

In the previous week, Sarepta Therapeutics had 1 more articles in the media than Upstream Bio. MarketBeat recorded 4 mentions for Sarepta Therapeutics and 3 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 1.23 beat Sarepta Therapeutics' score of 0.82 indicating that Upstream Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Upstream Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Upstream Bio (UPB) Competitors

$7.40 -0.23 (-3.04%)

As of 01:22 PM Eastern

Compare

UPB vs. LKFT, NRIX, RAPP, OCUL, and SRPT

Should you buy Upstream Bio stock or one of its competitors? MarketBeat compares Upstream Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Upstream Bio include Lakefront Biotherapeutics American Depositary Shares (LKFT), Nurix Therapeutics (NRIX), Rapport Therapeutics (RAPP), Ocular Therapeutix (OCUL), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical products" industry.

How does Upstream Bio compare to Lakefront Biotherapeutics American Depositary Shares?

Upstream Bio (NASDAQ:UPB) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. 16.5% of Upstream Bio shares are held by company insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Upstream Bio presently has a consensus price target of $38.20, indicating a potential upside of 416.36%. Lakefront Biotherapeutics American Depositary Shares has a consensus price target of $36.50, indicating a potential upside of 30.50%. Given Upstream Bio's stronger consensus rating and higher possible upside, analysts plainly believe Upstream Bio is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upstream Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Lakefront Biotherapeutics American Depositary Shares	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Upstream Bio. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upstream Bio	$2.85M	141.26	-$143.44M	-$2.91	N/A
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.47	$363.05M	-$1.41	N/A

Upstream Bio has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market.

In the previous week, Upstream Bio had 1 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 3 mentions for Upstream Bio and 2 mentions for Lakefront Biotherapeutics American Depositary Shares. Upstream Bio's average media sentiment score of 1.23 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.61 indicating that Upstream Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Upstream Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lakefront Biotherapeutics American Depositary Shares	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Upstream Bio's net margin of -4,718.96%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Upstream Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upstream Bio	-4,718.96%	-43.82%	-42.27%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

Summary

Upstream Bio beats Lakefront Biotherapeutics American Depositary Shares on 9 of the 16 factors compared between the two stocks.

How does Upstream Bio compare to Nurix Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and Upstream Bio (NASDAQ:UPB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Nurix Therapeutics has a net margin of -411.37% compared to Upstream Bio's net margin of -4,718.96%. Upstream Bio's return on equity of -43.82% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-411.37%	-64.21%	-48.44%
Upstream Bio	-4,718.96%	-43.82%	-42.27%

Upstream Bio has lower revenue, but higher earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$83.98M	19.14	-$264.46M	-$3.16	N/A
Upstream Bio	$2.85M	141.26	-$143.44M	-$2.91	N/A

Nurix Therapeutics has a beta of 1.86, suggesting that its share price is 86% more volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market.

Nurix Therapeutics currently has a consensus price target of $30.46, suggesting a potential upside of 95.98%. Upstream Bio has a consensus price target of $38.20, suggesting a potential upside of 416.36%. Given Upstream Bio's higher probable upside, analysts clearly believe Upstream Bio is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Upstream Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Upstream Bio had 3 more articles in the media than Nurix Therapeutics. MarketBeat recorded 3 mentions for Upstream Bio and 0 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 1.89 beat Upstream Bio's score of 1.23 indicating that Nurix Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Nurix Therapeutics	Very Positive
Upstream Bio	Positive

Summary

Upstream Bio beats Nurix Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Upstream Bio compare to Rapport Therapeutics?

Rapport Therapeutics (NASDAQ:RAPP) and Upstream Bio (NASDAQ:UPB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Rapport Therapeutics currently has a consensus target price of $58.83, suggesting a potential upside of 57.43%. Upstream Bio has a consensus target price of $38.20, suggesting a potential upside of 416.36%. Given Upstream Bio's higher possible upside, analysts clearly believe Upstream Bio is more favorable than Rapport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Upstream Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Rapport Therapeutics has higher earnings, but lower revenue than Upstream Bio. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A
Upstream Bio	$2.85M	141.26	-$143.44M	-$2.91	N/A

In the previous week, Rapport Therapeutics had 1 more articles in the media than Upstream Bio. MarketBeat recorded 4 mentions for Rapport Therapeutics and 3 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 1.23 beat Rapport Therapeutics' score of 0.58 indicating that Upstream Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rapport Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Upstream Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rapport Therapeutics has a net margin of 0.00% compared to Upstream Bio's net margin of -4,718.96%. Rapport Therapeutics' return on equity of -24.78% beat Upstream Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	-24.78%	-23.44%
Upstream Bio	-4,718.96%	-43.82%	-42.27%

Rapport Therapeutics has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market.

Summary

Rapport Therapeutics beats Upstream Bio on 8 of the 13 factors compared between the two stocks.

How does Upstream Bio compare to Ocular Therapeutix?

Upstream Bio (NASDAQ:UPB) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

In the previous week, Ocular Therapeutix had 5 more articles in the media than Upstream Bio. MarketBeat recorded 8 mentions for Ocular Therapeutix and 3 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 1.23 beat Ocular Therapeutix's score of -0.17 indicating that Upstream Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Upstream Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ocular Therapeutix	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Upstream Bio presently has a consensus price target of $38.20, suggesting a potential upside of 416.36%. Ocular Therapeutix has a consensus price target of $23.78, suggesting a potential upside of 169.74%. Given Upstream Bio's higher possible upside, equities research analysts plainly believe Upstream Bio is more favorable than Ocular Therapeutix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upstream Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Ocular Therapeutix has a net margin of -558.24% compared to Upstream Bio's net margin of -4,718.96%. Upstream Bio's return on equity of -43.82% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upstream Bio	-4,718.96%	-43.82%	-42.27%
Ocular Therapeutix	-558.24%	-64.28%	-48.15%

59.2% of Ocular Therapeutix shares are held by institutional investors. 16.5% of Upstream Bio shares are held by company insiders. Comparatively, 2.3% of Ocular Therapeutix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Upstream Bio has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market.

Upstream Bio has higher earnings, but lower revenue than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upstream Bio	$2.85M	141.26	-$143.44M	-$2.91	N/A
Ocular Therapeutix	$51.95M	37.15	-$265.94M	-$1.46	N/A

Summary

Upstream Bio beats Ocular Therapeutix on 10 of the 17 factors compared between the two stocks.

How does Upstream Bio compare to Sarepta Therapeutics?

Sarepta Therapeutics (NASDAQ:SRPT) and Upstream Bio (NASDAQ:UPB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

86.7% of Sarepta Therapeutics shares are held by institutional investors. 6.9% of Sarepta Therapeutics shares are held by company insiders. Comparatively, 16.5% of Upstream Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Upstream Bio has lower revenue, but higher earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	0.80	-$713.41M	-$0.96	N/A
Upstream Bio	$2.85M	141.26	-$143.44M	-$2.91	N/A

Sarepta Therapeutics currently has a consensus price target of $27.17, indicating a potential upside of 63.70%. Upstream Bio has a consensus price target of $38.20, indicating a potential upside of 416.36%. Given Upstream Bio's stronger consensus rating and higher possible upside, analysts plainly believe Upstream Bio is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	6 Sell rating(s)	13 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.11
Upstream Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Sarepta Therapeutics has a beta of 0.21, meaning that its share price is 79% less volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market.

In the previous week, Sarepta Therapeutics had 1 more articles in the media than Upstream Bio. MarketBeat recorded 4 mentions for Sarepta Therapeutics and 3 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 1.23 beat Sarepta Therapeutics' score of 0.82 indicating that Upstream Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Upstream Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sarepta Therapeutics has a net margin of -2.94% compared to Upstream Bio's net margin of -4,718.96%. Sarepta Therapeutics' return on equity of 7.56% beat Upstream Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-2.94%	7.56%	2.94%
Upstream Bio	-4,718.96%	-43.82%	-42.27%

Summary

Upstream Bio beats Sarepta Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Upstream Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UPB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UPB vs. The Competition

Export

Metric	Upstream Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$403.80M	$3.34B	$6.43B	$12.45B
Dividend Yield	N/A	2.37%	2.69%	5.22%
P/E Ratio	-2.55	18.80	23.85	24.37
Price / Sales	141.26	320.09	522.03	117.40
Price / Cash	N/A	110.40	41.27	57.13
Price / Book	1.18	6.83	10.04	6.75
Net Income	-$143.44M	$24.09M	$3.56B	$337.03M
7 Day Performance	-11.08%	-2.36%	-0.82%	0.08%
1 Month Performance	N/A	N/A	N/A	-1.66%
1 Year Performance	-31.88%	48.79%	28.88%	34.01%

Upstream Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UPB Upstream Bio	2.3949 of 5 stars	$7.40 -3.0%	$38.20 +416.4%	-29.6%	$403.80M	$2.85M	N/A	38	Analyst Upgrade
LKFT Lakefront Biotherapeutics American Depositary Shares	2.399 of 5 stars	$27.67 +0.7%	$36.50 +31.9%	-3.9%	$1.81B	$1.26B	N/A	1,310
NRIX Nurix Therapeutics	3.1162 of 5 stars	$17.38 -0.7%	$30.46 +75.3%	+28.1%	$1.81B	$83.98M	N/A	300	Positive News
RAPP Rapport Therapeutics	3.1273 of 5 stars	$39.71 +5.3%	$58.83 +48.2%	+202.3%	$1.80B	N/A	N/A	N/A	Analyst Forecast
OCUL Ocular Therapeutix	2.7417 of 5 stars	$8.29 +0.7%	$23.78 +186.8%	+0.2%	$1.80B	$52.04M	N/A	230

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UPB) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Upstream Bio (UPB) Competitors

UPB vs. LKFT, NRIX, RAPP, OCUL, and SRPT

How does Upstream Bio compare to Lakefront Biotherapeutics American Depositary Shares?

Summary

How does Upstream Bio compare to Nurix Therapeutics?

Summary

How does Upstream Bio compare to Rapport Therapeutics?

Summary

How does Upstream Bio compare to Ocular Therapeutix?

Summary

How does Upstream Bio compare to Sarepta Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPB vs. The Competition

Upstream Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Upstream Bio (UPB) Competitors

UPB vs. LKFT, NRIX, RAPP, OCUL, and SRPT

How does Upstream Bio compare to Lakefront Biotherapeutics American Depositary Shares?

Do insiders and institutionals believe in UPB or LKFT?

Do analysts prefer UPB or LKFT?

Which has better earnings and valuation, UPB or LKFT?

Which has more risk & volatility, UPB or LKFT?

Does the media refer more to UPB or LKFT?

Is UPB or LKFT more profitable?

Summary

How does Upstream Bio compare to Nurix Therapeutics?

Is NRIX or UPB more profitable?

Which has better earnings & valuation, NRIX or UPB?

Which has more volatility & risk, NRIX or UPB?

Do analysts rate NRIX or UPB?

Does the media prefer NRIX or UPB?

Summary

How does Upstream Bio compare to Rapport Therapeutics?

Do analysts recommend RAPP or UPB?

Which has preferable earnings & valuation, RAPP or UPB?

Does the media refer more to RAPP or UPB?

Is RAPP or UPB more profitable?

Which has more volatility and risk, RAPP or UPB?

Summary

How does Upstream Bio compare to Ocular Therapeutix?

Does the media refer more to UPB or OCUL?

Do analysts rate UPB or OCUL?

Is UPB or OCUL more profitable?

Do institutionals & insiders have more ownership in UPB or OCUL?

Which has more risk & volatility, UPB or OCUL?

Which has better earnings and valuation, UPB or OCUL?

Summary

How does Upstream Bio compare to Sarepta Therapeutics?

Do institutionals and insiders believe in SRPT or UPB?

Which has stronger earnings & valuation, SRPT or UPB?

Do analysts prefer SRPT or UPB?

Which has more risk & volatility, SRPT or UPB?

Does the media prefer SRPT or UPB?

Is SRPT or UPB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPB vs. The Competition

Upstream Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools